Mirati Therapeutics Inc (NASDAQ:MRTX)’s share price traded up 1.4% during trading on Wednesday . The stock traded as high as $75.71 and last traded at $76.59. 8,161 shares changed hands during trading, a decline of 99% from the average session volume of 680,352 shares. The stock had previously closed at $75.52.

Several equities analysts have commented on the company. Cowen reissued a “buy” rating on shares of Mirati Therapeutics in a research report on Wednesday, March 13th. Zacks Investment Research raised Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a research report on Friday, February 22nd. BidaskClub raised Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday. Oppenheimer reissued a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, March 19th. Finally, Credit Suisse Group assumed coverage on Mirati Therapeutics in a research report on Monday, March 25th. They set an “outperform” rating and a $85.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $69.08.

The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -24.06 and a beta of 1.95.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.20). The firm had revenue of $1.24 million during the quarter. On average, equities research analysts predict that Mirati Therapeutics Inc will post -5 earnings per share for the current fiscal year.

In related news, CEO Charles M. Baum sold 51,810 shares of Mirati Therapeutics stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $75.67, for a total value of $3,920,462.70. Following the completion of the sale, the chief executive officer now directly owns 117,851 shares in the company, valued at approximately $8,917,785.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce L. A. Carter sold 3,000 shares of Mirati Therapeutics stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $75.20, for a total value of $225,600.00. Following the completion of the sale, the director now owns 3,000 shares of the company’s stock, valued at $225,600. The disclosure for this sale can be found here. Insiders have sold 641,851 shares of company stock valued at $45,709,698 over the last 90 days. Corporate insiders own 4.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in Mirati Therapeutics by 109.7% in the 1st quarter. FMR LLC now owns 4,606,270 shares of the biotechnology company’s stock worth $337,640,000 after buying an additional 2,409,882 shares in the last quarter. BlackRock Inc. increased its holdings in Mirati Therapeutics by 13.8% in the 1st quarter. BlackRock Inc. now owns 2,336,095 shares of the biotechnology company’s stock worth $171,236,000 after buying an additional 283,146 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Mirati Therapeutics by 88.6% in the 1st quarter. Janus Henderson Group PLC now owns 2,034,744 shares of the biotechnology company’s stock worth $149,147,000 after buying an additional 956,022 shares in the last quarter. Vanguard Group Inc. increased its holdings in Mirati Therapeutics by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,431,905 shares of the biotechnology company’s stock worth $67,443,000 after buying an additional 26,316 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in Mirati Therapeutics by 21.8% in the 4th quarter. Jennison Associates LLC now owns 1,216,464 shares of the biotechnology company’s stock worth $51,602,000 after buying an additional 217,960 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Mirati Therapeutics (MRTX) Trading 1.4% Higher” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/mirati-therapeutics-mrtx-trading-1-4-higher/3021328.html.

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

See Also: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.